Medpace Holdings, Inc. (MEDP) Return on Assets (ROA): 21.62%
Is Medpace Holdings, Inc.’s return on assets (ROA) high or low?
Medpace Holdings, Inc.'s return on assets (ROA) of 21.62% is 31% above its 5-year average of 16.45%, near the high end of its 5-year range (10.45%–22.84%).
As of Wednesday, June 17, 2026. 2.73% above its 12-month average of 21.05%.
MEDP Return on Assets (ROA) Chart
MEDP Average Return on Assets (ROA) Chart
MEDP Current vs Average Return on Assets (ROA) Chart
MEDP Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
21.62%
RETURN ON ASSETS (ROA) AVG TTM
21.05%
RETURN ON ASSETS (ROA) AVG 3Y
19.32%
RETURN ON ASSETS (ROA) AVG 5Y
16.45%
RETURN ON ASSETS (ROA) AVG 10Y
10.88%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+2.73%
CURRENT VS 3Y AVG
+11.88%
CURRENT VS 5Y AVG
+31.42%
CURRENT VS 10Y AVG
+98.75%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.18B | 21.62% | 21.05% | 19.32% | 16.45% |
| The Cooper Companies, Inc. (COO)vs › | $13.14B | 1.89% | 3.10% | 3.02% | 7.71% |
| Solventum Corporation (SOLV)vs › | $13.26B | 10.16% | 7.10% | 8.43% | 7.35% |
| DaVita Inc. (DVA)vs › | $13.42B | 4.47% | 4.84% | 4.27% | 4.56% |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 6.81% | 6.68% | 6.69% | 12.75% |
| Revvity, Inc. (RVTY)vs › | $11.29B | 2.01% | 2.19% | 1.89% | 3.83% |
| Baxter International Inc. (BAX)vs › | $10.57B | -5.53% | -3.64% | -1.62% | 0.47% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -9.07% | -6.92% | -1.48% | 0.07% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 5.92% | 7.45% | 8.56% | 11.79% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | -2.39% | -0.94% | 2.58% | 3.75% |
Asset Efficiency
ROA
21.6%
ROE
77.0%
Medpace Holdings, Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Medpace Holdings, Inc. (MEDP)?
- The return on assets (ROA) for MEDP stock is 21.62%.
- Is Medpace Holdings, Inc.'s return on assets (ROA) high or low?
- Medpace Holdings, Inc.'s return on assets (ROA) of 21.62% is 31% above its 5-year average of 16.45%, near the high end of its 5-year range (10.45%–22.84%).
- What is the TTM average return on assets (ROA) for Medpace Holdings, Inc. (MEDP)?
- The TTM average return on assets (ROA) for MEDP stock is 21.05%.
- What is the 3Y average return on assets (ROA) for Medpace Holdings, Inc. (MEDP)?
- The 3Y average return on assets (ROA) for MEDP stock is 19.32%.
- What is the 5Y average return on assets (ROA) for Medpace Holdings, Inc. (MEDP)?
- The 5Y average return on assets (ROA) for MEDP stock is 16.45%.
- What is the 10Y average return on assets (ROA) for Medpace Holdings, Inc. (MEDP)?
- The 10Y average return on assets (ROA) for MEDP stock is 10.88%.
Medpace Holdings, Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 22.84% |
| 2024-12-31 | 19.25% |
| 2023-12-31 | 17.07% |
| 2022-12-31 | 18.14% |
| 2021-12-31 | 10.96% |
| 2020-12-31 | 10.45% |
| 2019-12-31 | 8.79% |
| 2018-12-31 | 7.56% |
| 2017-12-31 | 4.11% |
| 2016-12-31 | 1.37% |
| 2015-12-31 | -0.88% |
| 2014-12-31 | -1.42% |
| 2013-12-31 | 0.00% |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle